BiomX Inc. (PHGE)
- Previous Close
0.4180 - Open
0.4000 - Bid 0.3558 x 4000
- Ask 0.4134 x 1300
- Day's Range
0.3701 - 0.4134 - 52 Week Range
0.1870 - 0.8550 - Volume
204,153 - Avg. Volume
320,915 - Market Cap (intraday)
25.835M - Beta (5Y Monthly) 1.32
- PE Ratio (TTM)
-- - EPS (TTM)
-0.5900 - Earnings Date Aug 7, 2024 - Aug 12, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
BiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic disease. It is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis. The company's product pipeline also includes BX004, a phage therapy for cystic fibrosis patients with chronic pulmonary infections caused by Pseudomonas aeruginosa that is in Phase 1b/2a clinical trials. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.
www.biomx.comRecent News: PHGE
Performance Overview: PHGE
Trailing total returns as of 6/6/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PHGE
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PHGE
Valuation Measures
Market Cap
25.84M
Enterprise Value
-7.05M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
6.54
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-25.59%
Return on Equity (ttm)
-190.33%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-37.13M
Diluted EPS (ttm)
-0.5900
Balance Sheet and Cash Flow
Total Cash (mrq)
43.01M
Total Debt/Equity (mrq)
44.26%
Levered Free Cash Flow (ttm)
-11.23M